Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPHT message board posts where the ticker symbol OPHT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPHT SEC Filings

Filings Format Description Filing Date File/Film Number
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-010303 (34 Act)  Size: 10 KB
2017-12-04 001-36080
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001410939-17-000028 (34 Act)  Size: 6 MB
2017-11-08 001-36080
8-K  Documents Current report, item 2.02
Acc-no: 0001410939-17-000027 (34 Act)  Size: 155 KB
2017-11-08 001-36080
8-K  Documents Current report, item 1.01
Acc-no: 0001410939-17-000022 (34 Act)  Size: 19 KB
2017-11-07 001-36080
8-K  Documents Current report, item 1.02
Acc-no: 0001410939-17-000019 (34 Act)  Size: 24 KB
2017-10-27 001-36080
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-008759 (34 Act)  Size: 14 KB
2017-09-19 001-36080
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001410939-17-000017 (34 Act)  Size: 60 KB
2017-08-14 001-36080
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001410939-17-000014 (33 Act)  Size: 414 KB
2017-08-03 333-219656
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001410939-17-000011 (34 Act)  Size: 6 MB
2017-08-02 001-36080
8-K/A  Documents [Amend] Current report, item 7.01
Acc-no: 0001410939-17-000008 (34 Act)  Size: 3 MB
2017-07-26 001-36080
More OPHT SEC Filings

Related news from
Tue, 12 Dec 2017
22:49:10 +0000
Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
Mon, 11 Dec 2017
10:02:10 +0000
Ophthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue?
Ophthotech (OPHT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tue, 21 Nov 2017
12:50:00 +0000
Report: Exploring Fundamental Drivers Behind Carter's, Southern Copper, ViaSat, Bruker, Fred's, and Ophthotech — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 21, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carter's, ...
Mon, 20 Nov 2017
18:01:25 +0000
ETFs with exposure to Ophthotech Corp. : November 20, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ophthotech Corp. Here are 5 ETFs with the largest exposure to OPHT-US. Comparing the performance and risk of Ophthotech Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more <b>(Read more...)</b>
Tue, 14 Nov 2017
13:43:01 +0000
Ophthotech (OPHT) Jumps: Stock Rises 11.9%
Ophthotech Corporation (OPHT) saw its shares rise nearly 12% on the day.
Tue, 14 Nov 2017
01:31:01 +0000
Edited Transcript of OPHT earnings conference call or presentation 8-Nov-17 1:00pm GMT
Q3 2017 Ophthotech Corp Earnings Call
Mon, 13 Nov 2017
19:20:07 +0000
Vertex Gets CHMP Recommendation for Orkambi Label Expansion
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Thu, 09 Nov 2017
14:48:38 +0000
Ophthotech Corp. :OPHT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
Categories: Yahoo FinanceGet free summary analysis Ophthotech Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Ophthotech Corp. – Alimera Sciences, Inc., Insmed Incorporated and Nektar Therapeutics (ALIM-US, INSM-US and NKTR-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 206.65 ... Read more <b>(Read more...)</b>
Thu, 09 Nov 2017
14:16:02 +0000
Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus
Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.
Thu, 09 Nov 2017
13:10:00 +0000
Today’s Research Reports on Stocks to Watch: Ophthotech Corporation and HTG Molecular Diagnostics
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Ophthotech and HTG Molecular Diagnostics both saw green on Wednesday after announcing strong third quarter reports. Ophthotech also announced that it is on ...
Wed, 08 Nov 2017
14:30:00 +0000
Ophthotech Soars After Third-Quarter Results -- Biotech Movers
The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.
Wed, 08 Nov 2017
12:22:02 +0000
Ophthotech posts 3Q profit
On a per-share basis, the New York-based company said it had profit of $5.25. The clinical-stage biotech focused on eye diseases posted revenue of $206.7 million in the period. The company's shares closed ...
Wed, 08 Nov 2017
12:00:00 +0000
Ophthotech Reports Third Quarter 2017 Financial and Operating Results
Ophthotech Corporation today announced financial and operating results for the third quarter ended September 30, 2017 and provided a business update.
Wed, 08 Nov 2017
11:00:00 +0000
Ophthotech Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Ophthotech Corp. (NASDAQ: OPHT ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:00 AM Eastern Time. ...
Mon, 30 Oct 2017
11:30:00 +0000
Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
Ophthotech Corporation today announced that it will report its third quarter 2017 financial and operating results on Wednesday, November 8, 2017. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.
Mon, 09 Oct 2017
18:19:14 +0000
How Should You Think About Ophthotech Corporation’s (OPHT) Risks?
If you are looking to invest in Ophthotech Corporation’s (NASDAQ:OPHT), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
Thu, 21 Sep 2017
14:15:02 +0000
How is the Age-Related Macular Degeneration Space Faring Now?
The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
Tue, 19 Sep 2017
11:00:00 +0000
Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases
Ophthotech Corporation announced today the initiation of an open-label Phase 2a clinical trial of Zimura® , the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration .
Mon, 11 Sep 2017
13:42:01 +0000
Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "Since being one of the beginning members, it has been a great experience. This select group of sophisticated investors has exceptional knowledge to share. The members come from all walks of life and have varied experiences. Many are experts in finance and commodity related issues. Many are good money managers. This is a value oriented group where good yields on a variety of stocks are the main focus." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards